Effect of media composition and in vitro activity of posaconazole, caspofungin and voriconazole against zygomycetes

被引：20

作者：

Gil-Lamaignere, C

Hess, R

Salvenmoser, S

Heyn, K

Kappe, R

Müller, FMC

机构：

[1] Univ Heidelberg, Dept Paediat 3, D-69120 Heidelberg, Germany

[2] Helios Med Ctr, Haema Inst Lab Med, Erfurt, Germany

来源：

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY | 2005年 / 55卷 / 06期

关键词：

rhizopus; mucor; absidia; rhizomucor; cunninghamella;

D O I：

10.1093/jac/dki140

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Objectives: The effect of different media and composition on the in vitro activity of posaconazole, caspofungin and voriconazole against 59 zygomycetes species was determined. Methods: The media tested were, RPMI 1640 medium with and without 25 glucose antibiotic medium 3 (AM3) with and without.2% glucose, and high resolution (HR) medium. Results: Posaconazole was significantly more active than caspofungin and voriconazole both in RPMI 1640 medium with 2% glucose and in HR medium. Adding glucose improved the determination of end points, but had only minor influence on the MICs. MICs evaluated in AM3 were lower than in RPMI 1640 medium or HR medium. Conclusions: The in vivo effect of posaconazole in zygomycosis needs further evaluation.

引用

收藏

页码：1016 / 1019

页数：4

相关论文

共 13 条

[1] Microdilution susceptibility testing of amphotericin B, itraconazole, and voriconazole against clinical isolates of Aspergillus and Fusarium species [J].

Arikan, S ;

Lozano-Chiu, M ;

Paetznick, V ;

Nangia, S ;

Rex, JH .

JOURNAL OF CLINICAL MICROBIOLOGY, 1999, 37 (12) :3946-3951

[2] Quality control limits for broth microdilution susceptibility tests of ten antifungal agents [J].

Barry, AL ;

Pfaller, MA ;

Brown, SD ;

Espinel-Ingroff, A ;

Ghannoum, MA ;

Knapp, C ;

Rennie, RP ;

Rex, JH ;

Rinaldi, MG .

JOURNAL OF CLINICAL MICROBIOLOGY, 2000, 38 (09) :3457-3459

[3] Influences of methodological variables on susceptibility testing of caspofungin against Candida species and Aspergillus fumigatus [J].

Bartizal, C ;

Odds, FC .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (07) :2100-2107

[4] Activity of posaconazole in treatment of experimental disseminated zygomycosis [J].

Dannaoui, E ;

Meis, JFGM ;

Loebenberg, D ;

Verweij, PE .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (11) :3647-3650

[5] In vitro susceptibilities of zygomycetes to conventional and new antifungals [J].

Dannaoui, E ;

Meletiadis, J ;

Mouton, JW ;

Meis, JFGM ;

Verweij, PE .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 51 (01) :45-52

[6] Posaconazole: a potent, extended-spectrum triazole anti-fungal for the treatment of serious fungal infections [J].

Herbrecht, R .

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2004, 58 (06) :612-624

[7]

HESSIAN PA, 1982, SABOURAUDIA, V20, P209

[8] Effect of the growth medium on the in vitro antifungal activity of micafungin (FK-463) against clinical isolates of Candida dubliniensis [J].

Müller, FMC ;

Kurzai, O ;

Hacker, J ;

Frosch, M ;

Mühlschlegel, F .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 48 (05) :713-715

[9]

National Committee for Clinical Laboratory Standards, 2002, M38A NAT COMM CLIN L

[10] DETECTION OF AMPHOTERICIN B-RESISTANT CANDIDA ISOLATES IN A BROTH-BASED SYSTEM [J].

REX, JH ;

COOPER, CR ;

MERZ, WG ;

GALGIANI, JN ;

ANAISSIE, EJ .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (04) :906-909